tbuckley/cabot-search huggingface dataset:
Head-to-Head Comparison of 18F-Prostate-Specific Membrane Antigen-1007 and 18F-Fluorocholine PET/CT in Biochemically Relapsed Prostate Cancer
Authors: Ewa Witkowska-Patena, Agnieszka Giżewska, Mirosław Dziuk, Jolanta Miśko, Anna Budzyńska, Agata Walęcka-Mazur
Journal: Clinical Nuclear Medicine (2019)

Purpose of the Report The aim of the study was to prospectively compare performance of 18 F-fluorocholine (FCH) and 18 F-prostate-specific membrane antigen (PSMA)-1007 PET/CT in patients with biochemical relapse (BCR) of prostate cancer and low prostate-specific antigen levels. Methods We prospectively enrolled 40 BCR patients after radical treatment and prostate-specific antigen levels 2.0 ng/mL or less. 18 F-FCH and 18 F-PSMA-1007 PET/CT imaging was performed within a mean interval of 54 ± 21 days. Scans were done 87 ± 10 and 95 ± 12 minutes after injecting 248 ± 35 and 295 ± 14 MBq of 18 F-FCH and 18 F-PSMA-1007, respectively. Rates of negative, equivocal, and positive scan results were compared per patient. Per lesion, findings were grouped as equivocal or highly suggestive of malignancy and then compared for their number, localization (local relapse, lymph nodes, bones), and SUVmax values. Results Positive, equivocal, and negative results were reported in 60%, 27.5%, and 12.5% of 18 F-PSMA-1007 and in 5%, 37.5%, and 57.5% of 18 F-FCH scans, respectively. In 70% of scans, 18 F-PSMA-1007 PET/CT upgraded 18 F-FCH PET/CT results. 18 F-PSMA-1007 scans also showed significantly more lesions (184 vs 63, P = 0.0006). Local relapse, lymph node, and bone lesions accounted, respectively, for 9%, 58%, and 33% of 18 F-PSMA-1007 and 5%, 89%, and 6% 18 F-FCH of PET/CT findings. Highly suspicious lesions accounted for 74% of 18 F-PSMA-1007 and 11% of 18 F-FCH PET/CT findings. In 18 F-PSMA-1007 PET/CT SUVmax values of highly suggestive lesions were significantly higher than in equivocal lesions (median, 3.6 vs 2.5; P &lt; 0.00001). Conclusions In early BCR patients 18 F-PSMA-1007 showed a higher detection rate than 18 F-FCH PET/CT. The former also showed more lesions in total, more highly suggestive lesions and less equivocal lesions.
Enhancer Rewiring Dependent Switch from BCL2 to MCL1 Dependency Predicts NOTCH1 Inhibition Response in T-ALL
Authors: Valeriya Dimitrova, Huiyoung Yun, Sayalee Potdar, Alexandria Nicole Van Scoyk, Shruti Bhatt, Praveen Anand, Monica S. Nair, Jake A. Kloeber, Antonis Kokkalis, Julia Frede, Johannes M. Waldschmidt, Anthony G. Letai, David M. Weinstock, Jon C. Aster, Jens G. Lohr, Birgit Knoechel
Journal: Blood (2019)
A Multicenter Phase II Single Arm Trial of Isatuximab in Patients with High Risk Smoldering Multiple Myeloma (HRSMM)
Authors: Elisabet E. Manasanch, Sundar Jagannath, Hans C. Lee, Krina K. Patel, Connor Graham, Gregory P. Kaufman, Sheeba K. Thomas, Swami Iyer, Sham Mailankody, Neha Korde, Behrang Amini, Pei Lin, Zuzana Berkova, Donna M. Weber, Feng Lei, Nikoletta Lendvai, Michelle Hildebrandt, Sattva S Neelapu, Robert Z. Orlowski, Ola Landgren
Journal: Blood (2019)
RTHP-39. SPINAL CORD DELINEATION BASED ON CT MYELOGRAM VERSUS T2 MRI IN SPINE SBRT CASES
Authors: Lubna Hammoudeh, Ho Young Lee, Jeffrey Guenette, Tracy Balboni
Journal: Neuro-Oncology (2019)

Abstract PURPOSE/OBJECTIVE(S) Spinal cord (SC) delineation is critical in spine SBRT. While underestimating cord can lead to myelitis, overestimating SC may compromise PTV coverage, resulting in higher rates of tumor recurrence. CT myelogram as part of CT simulation is a radiological means of better visualizing the SC and minimizing MRI fusion error. The aim of this study is to compare SC contours based on CT simulation with myelogram and with fused MRI. MATERIALS/METHODS Eight patients with 9 spinal metastases treated with spine SBRT were evaluated. All patients had spinal MRI and myelogram performed prior to CT simulation. The spinal MRI was fused and the SC volume was contoured from the superior to the inferior endplate of the target vertebral body volume based on the (1) CT myelogram images and (2) fused T2 MRI images. Comparing MRI to myelogram-defined SC, centroid deviations (deviations in the center point of the cord) were assessed at every slice through the VB target volume, and maximum deviations of the cord were assessed; all are reported with descriptive statistics. The SC cc volume based on CT myelogram and MRI were compared using paired t-test. RESULTS Between MRI- versus myelogram- defined SC volumes, average deviations of the centroid point cord contours was 0.06cm, ranging from 0.01-0.1cm; average deviation of the outmost aspect of the contours were on average between 0.07-0.11cm. Finally, the volume of the cord was significantly smaller when defined on MRI as compared to myelogram - 2.778cc (SD=0.98) vs. 3.44cc (SD=1.43), p=0.03 - respectively There was only one case that had a SC volume based on T2 MRI that was bigger than that based on myelogram (3.5cc vs. 2.9cc). CONCLUSIONS These data suggest average deviations on MRI of approximately 0.1cm, largely undercontouring the SC volume based on MRI as compared to CT simulation with myelogram.
CRUP: a comprehensive framework to predict condition-specific regulatory units
Authors: Anna Ramisch, Verena Heinrich, Laura V. Glaser, Alisa Fuchs, Xinyi Yang, Philipp Benner, Robert Schöpflin, Na Li, Sarah Kinkley, Anja Römer-Hillmann, John Longinotto, Steffen Heyne, Beate Czepukojc, Sonja M. Kessler, Alexandra K. Kiemer, Cristina Cadenas, Laura Arrigoni, Nina Gasparoni, Thomas Manke, Thomas Pap, John A. Pospisilik, Jan Hengstler, Jörn Walter, Sebastiaan H. Meijsing, Ho-Ryun Chung, Martin Vingron
Journal: Genome biology (2019)

Abstract We present the software Condition-specific Regulatory Units Prediction (CRUP) to infer from epigenetic marks a list of regulatory units consisting of dynamically changing enhancers with their target genes. The workflow consists of a novel pre-trained enhancer predictor that can be reliably applied across cell types and species, solely based on histone modification ChIP-seq data. Enhancers are subsequently assigned to different conditions and correlated with gene expression to derive regulatory units. We thoroughly test and then apply CRUP to a rheumatoid arthritis model, identifying enhancer-gene pairs comprising known disease genes as well as new candidate genes.
TMIC-42. LOCAL TISSUE METABOLOMICS BASED BIOMARKERS OF RESPONSE TO THERAPY FOR GLIOBLASTOMA
Authors: Karishma Rajani, Lucas Carlstrom, Joshua Jacobs, Mark Schroeder, Ian Olson, Xuewei Wang, Jann Sarkaria, Terry Burns
Journal: Neuro-Oncology (2019)

Abstract Glioblastoma (GBM) is a common deadly malignant brain cancer of the central nervous system (CNS), with a median survival of 12–15 months. Scientific advancements are lacking in developing effective therapies for both primary GBM, as well as secondary GBMs, that typically originate as malignant transformation of lower-grade isocitrate dehydrogenase (IDH) 1-mutant tumors. The unique metabolomic profile of IDH1-mutant tumors may present opportunities to develop biomarker signatures of therapeutic efficacy. Microdialysis is an extracellular fluid sampling collection technique utilizing a perfused semipermeable catheter to permit diffusion of molecules between brain interstitium and the perfusate. We hypothesized that microdialysis may identify a metabolomics-based biomarker response to therapy in IDH1-mutant tumors. To test this hypothesis, orthotopic xenografts were generated from two patient-derived GBM lines harboring mutations in IDH1. Perfusates were collected from intra-cranial tumors in aythmic nude mice sampled at baseline and 72h post treatment with temozolomide, an oral alkylating agent used to treat IDH1-mutant gliomas, compared with vehicle treatment, and TMZ-treated non-tumor bearing animals. Perfusates were analyzed via unsupervised metabolomic profiling using both gas and liquid chromatography-mass spectrometry (GC/LC-MS). Tumor specific metabolites such as carnitine and pyruvic acid were detected in microdialysate from tumor bearing mice compared to non-tumor bearing mice. Microdialysis is a feasible technology to identify metabolomics-based biomarker in IDH1-mutant PDX. This work is complemented by parallel analysis of non-IDH1-mutant and TMZ resistant xenografts to yield predictive in vivo tissue biomarkers of drug responsiveness translatable to clinical practice.
BTK and/or PLCG2 Mutations in Patients with Chronic Lymphocytic Leukemia (CLL) Treated with Ibrutinib: Characteristics and Outcomes at the Time of Progression
Authors: Paul J. Hampel, Timothy G. Call, Sara J. Achenbach, Kari G Rabe, Wei Ding, Eli Muchtar, Saad S. Kenderian, Yucai Wang, Amber Koehler, Amie Fonder, Jose F. Leis, Susan M. Schwager, Daniel L. Van Dyke, Esteban Braggio, Susan L. Slager, Neil E. Kay, Sameer A. Parikh
Journal: Blood (2019)
CD38 Deregulation As Strategy to Make Multiple Myeloma Cells More Sensitive to NAD+ Depleting Agents
Authors: Michele Cea, Antonia Cagnetta, Debora Soncini, Paola Minetto, Micaela Bergamaschi, Giulia Rivoli, Letizia Canepa, Marco Gobbi, Roberto M Lemoli
Journal: Blood (2016)
Incidental Detection of a Giant Fecaloma on 18F-FDG PET/CT
Authors: Nicolas Plouznikoff
Journal: Clinical Nuclear Medicine (2019)

Abstract Fecal retention can be exacerbated in older patients, bedridden patients, as well as those receiving opioids analgesics or anticholinergic medications. It can lead to impaction, which can have serious consequences, sometimes even requiring surgical intervention. We describe herein the incidental detection of a giant hypometabolic fecaloma on PET/CT with 18 F-FDG during the initial staging of a patient with osteosarcoma using opioids for pain management.
Superior Outcomes in Relapsed/Refractory Childhood B-ALL Than Adult Patients with CD19 CAR-T Cell Therapy: A Single-Center Pilot Prospective Study of 23 Patients
Authors: Tingting Li, Luting Luo, Jinhua Ren, Xiaofeng Luo, Zhihong Zheng, Hao Zheng, Zhizhe Chen, Gangxiong Huang, Ting Yang, Jianda Hu
Journal: Blood (2019)
Deconvolution of Hematopoietic Commitment Decisions By Genome-Wide Analysis of Progressive DNA Methylation Changes
Authors: Sina Staeble, Stephen Kraemer, Jens Langstein, Ruzhica Bogeska, Mark Hartmann, Maximilian Schoenung, Melinda Czeh, Julia Knoch, Natasha Anstee, Simon Haas, Abdelrahman Mahmoud, Julius Graesel, Daniel Huebschmann, Lars Feuerbach, Weichenhan Dieter, Benedikt Brors, Karsten Rippe, Jan-Philipp Mallm, Frank Rosenbauer, Christoph Plass, Matthias Schlesner, Michael D. Milsom, Daniel B. Lipka
Journal: Blood (2019)
New Zealand will hold referendum on assisted dying in 2020
Authors: Elisabeth Mahase
Journal: BMJ (2019)

The New Zealand government has announced a public referendum on euthanasia which, if passed, will allow assisted dying for terminally ill patients with two doctors’ approval.1

This is the first time a country has held such a vote on assisted dying, coming after lawmakers passed the End of Life Choice Bill in parliament by 69 votes to 51. The bill stipulates that terminally ill people with less than six months to live would be able to choose assisted dying if two doctors approved.

The referendum is set to coincide with the country’s 2020 elections. The ballot paper will also include a vote on whether to legalise personal use of cannabis and, potentially, decriminalisation of abortion.2

Countries where assisted dying is currently legal under certain circumstances include …
Anti-Bcma PBD MEDI2228 Combats Drug Resistance and Synergizes with Bortezomib and Inhibitors to DNA Damage Response in Multiple Myeloma
Authors: Lijie Xing, Liang Lin, Tengteng Yu, Yuyin Li, Kenneth Wen, Shih-Feng Cho, Phillip A Hsieh, Krista Kinneer, Nikhil C. Munshi, Kenneth C. Anderson, Yu-Tzu Tai
Journal: Blood (2019)
Inhibiting Very Long Chain Acyl-CoA Dehydrogenase (VLCAD) Induces Selective Leukemia Cell Death
Authors: Matthew Tcheng, Alessia Roma, Nawaz Ahmed, Richard Smith, Preethi Jayanth, Mark D. Minden, Rose Hurren, Aaron D Schimmer, Gale Bozzo, David Hess, Kristin Hope, Kevin Rea, Tariq A. Akhtar, Al-Walid Mohsen, Jerry Vockley, Paul A. Spagnuolo
Journal: Blood (2019)
Abstract 18754: Genetic Predisposition to Coronary Artery Disease and Changes in Lipid Profile in Response to 2-year Weight-loss Diet Intervention: The Pounds Lost Trial
Authors: Tiange Wang, Tao Huang, Yan Zheng, George Bray, Frank M Sacks, Lu Qi
Journal: Circulation (2015)

Introduction: Dyslipidemia is a major risk factor of coronary artery disease (CAD), and is affected by interaction between genetic and environmental factors, such as diets. Weight-loss diet intervention has been widely used to improve lipids to mitigate cardiovascular complications of obesity. Hypothesis: We hypothesize that the genetic predisposition to CAD may modify lipids metabolism in response to diets. Methods: We calculated a genetic risk score (GRS) based on 19 CAD-associated single nucleotide polymorphisms in 744 adults from a 2-year diet intervention study: the POUNDS Lost trial. We examined the changes in total cholesterol, high-density lipoprotein (HDL) cholesterol, low-density lipoprotein (LDL) cholesterol and triglycerides by the GRS and diet intervention. Results and Conclusions: We found significant interaction between the GRS and dietary fat intake on changes in total cholesterol, HDL and LDL cholesterol (P-interaction=0.02, 0.01 and 0.02, respectively) after the 2-year intervention. Overall, both low- and high-fat diets decreased total cholesterol, LDL cholesterol and triglycerides, but increased HDL cholesterol. At 2 years, in the highest tertile of the GRS, participants eating the low-fat diet showed a greater decrease in total cholesterol and LDL cholesterol than those eating the high-fat diet; whereas participants eating the high-fat diet showed a greater increase in HDL cholesterol than those eating the low-fat diet (all P&lt;0.001). In lower tertiles of the GRS, the difference in lipids changes between the two diet groups was not significant. In conclusion, genetic predisposition to CAD might modify the dietary fat induced lipids changes. Our data suggest that in participants with higher genetic risk, low-fat diet may lower total cholesterol and LDL cholesterol, while high-fat diet may improve HDL cholesterol. And in participants with lower genetic risk, the two diets showed similar effects on improvement of lipid profile.
Obituary: Johan Willem Mouton
Authors: J. Kluytmans, A. Voss, G. Kahlmeter, C. Giske, A. MacGowan, D. Brown, S. Gatermann, G. Lina, C. Lindemann, J. Turnidge, R. Canton, E. Petinaki, C. Pina Vaz, J. Rodriguez Baño
Journal: Clinical Microbiology and Infection (2019)
Circ-HuR suppresses HuR expression and gastric cancer progression by inhibiting CNBP transactivation
Authors: Feng Yang, Anpei Hu, Dan Li, Jianqun Wang, Yanhua Guo, Yang Liu, Hongjun Li, Yajun Chen, Xiaojing Wang, Kai Huang, Liduan Zheng, Qiangsong Tong
Journal: Molecular Cancer (2019)

Circular RNAs (circRNAs), a subclass of non-coding RNAs, play essential roles in tumorigenesis and aggressiveness. Our previous study has identified that circAGO2 drives gastric cancer progression through activating human antigen R (HuR), a protein stabilizing AU-rich element-containing mRNAs. However, the functions and underlying mechanisms of circRNAs derived from HuR in gastric cancer progression remain elusive.CircRNAs derived from HuR were detected by real-time quantitative RT-PCR and validated by Sanger sequencing. Biotin-labeled RNA pull-down, mass spectrometry, RNA immunoprecipitation, RNA electrophoretic mobility shift, and in vitro binding assays were applied to identify proteins interacting with circRNA. Gene expression regulation was observed by chromatin immunoprecipitation, dual-luciferase assay, real-time quantitative RT-PCR, and western blot assays. Gain- and loss-of-function studies were performed to observe the impacts of circRNA and its protein partner on the growth, invasion, and metastasis of gastric cancer cells in vitro and in vivo.Circ-HuR (hsa_circ_0049027) was predominantly detected in the nucleus, and was down-regulated in gastric cancer tissues and cell lines. Ectopic expression of circ-HuR suppressed the growth, invasion, and metastasis of gastric cancer cells in vitro and in vivo. Mechanistically, circ-HuR interacted with CCHC-type zinc finger nucleic acid binding protein (CNBP), and subsequently restrained its binding to HuR promoter, resulting in down-regulation of HuR and repression of tumor progression.Circ-HuR serves as a tumor suppressor to inhibit CNBP-facilitated HuR expression and gastric cancer progression, indicating a potential therapeutic target for gastric cancer.
Conditioning Regimen Intensity May Affect Outcome in MDS Patients Undergoing Allogeneic Stem Cell Transplantation, Depending on MDS Subgroup
Authors: Barry S. Skikne, Anurag K. Singh, Sunil Abhyankar, Tara L. Lin, Leyla Shune, Neil Dunavin, Ajoy L. Dias, Brian McClune, Abdulraheem Yacoub, Clint Divine, Haitham Abdelhakim, Siddhartha Ganguly, Jennifer Hanses, Carol E Webb, Joseph P. McGuirk
Journal: Blood (2019)
Imatinib +/- Brentuximab Vedotin Induces Sustained Complete Remission in Chemotherapy-Resistant Anaplastic Large Cell Lymphoma Expressing PDGFR
Authors: Philipp Bernhard Staber, Christoph Kornauth, Ines Garces de los Fayos Alonso, Wilhelm Woessmann, Wolfram Klapper, Sabine Lagger, Ana-Iris Schiefer, Cathrin Skrabs, Olaf Merkel, Marius E Mayerhoefer, Richard Greil, Ingrid Simonitsch-Klupp, Lukas Kenner, Ulrich Jaeger
Journal: Blood (2019)
Early Organ Toxicity Following Allogeneic Hematopoietic Stem Cell Transplantation Differs By Conditioning Regimen
Authors: Joshua A Fein, Avichai Shimoni, Ivetta Danylesko, Noga Shem-Tov, Ronit Yerushalmi, Guy Chowers, Zachary Cohen, Arnon Nagler, Roni Shouval
Journal: Blood (2019)
Mitochondrial Activity Identifies a Transcriptionally and Functionally Distinct Subset of Aged HSCs with Lineage-Balanced Output
Authors: Els Mansell, Valgardur Sigurdsson, Elitza Deltcheva, John Brown, Chela James, Kenichi Miharada, Shamit Soneji, Jonas Larsson, Tariq Enver
Journal: Blood (2019)
BCR-ABL1 qPCR-Based Doubling Time within the First 6 Months after Imatinib Discontinuation Is a Predictive of Successful TKI Treatment-Free Remission
Authors: Georgina S. Daher-Reyes, Isabelle Bence-Bruckler, Lambert Busque, Donna L. Forrest, Lynn Savoie, Mary-Margaret Keating, Robert Delage, Anargyros Xenocostas, Elena Liew, Pierre Laneuville, Kristjan Paulson, Jeffrey H. Lipton, Suzanne Kamel-Reid, Brian Leber, Dennis Dong Hwan Kim
Journal: Blood (2019)
Abstract 15852: Treated Systolic Blood Pressure and Cardiovascular Risk in Adults With Hypertension and Type 2 Diabetes: Results From the TECOS Trial
Authors: Ann M Navar, Dianne S Gallup, Yuliya Lokhnygina, Jennifer B Green, Darren K McGuire, Paul W Armstrong, John B Buse, Samuel S Engel, John M Lachin, Eberhard Standl, Frans Van de Werf, Rury R Holman, Eric D Peterson
Journal: Circulation (2016)

Background: SBP treatment targets for adults with type 2 diabetes (T2D) remain unclear. Methods: The relationship between SBP and CVD events was evaluated in patients with medically treated HTN in ...
An External Validation Study for Current Risk Scoring Models in Elderly Patients with Newly Diagnosed Acute Myeloid Leukemia
Authors: Chia-Jen Liu, Hong Ying-Chung, Chiu-Mei Yeh, Chun-Kuang Tsai, Liang-Tsai Hsiao, Hao-Yuan Wang, Yao-Chung LIU, Jyh-Pyng Gau, Po-Shen Ko, Jin-Hwang Liu, Po-Min Chen
Journal: Blood (2019)
Global Rnaseq/Proteomic-Phoshoproteomic Analysis Unveil Mir-21 As a Central Player in Driving Th17 Mediated Bone Disease in MM
Authors: Marco Rossi, Emanuela Altomare, Cirino Botta, Maria Eugenia Gallo Cantafio, Marco Gaspari, Domenico Taverna, Sarvide Sarai, Daniele Caracciolo, Paola Critelli, Francesco Conforti, Maria Teresa Di Martino, Bruno Paiva, Pierosandro Tagliaferri, Pierfrancesco Tassone
Journal: Blood (2019)
Biodistribution and Efficacy of L-Annamycin in a Novel Imageable AML Mouse Model
Authors: Rafal Zielinski, Krzysztof Grela, Stanislaw Skora, Rodrigo Jacamo, Izabela Fokt, Matthew Sander, Magdalena Remiszewski, Edward Felix, Meenakshi Shanmugasundaram, Malgorzata Anna Zal, Michael Andreeff, Waldemar Priebe, Tomasz Zal
Journal: Blood (2019)
Allogeneic Hematopoietic Stem Cell Transplantation (allo-HSCT) with Different Intensity Conditioning Regimens in Children with Very High Risk Acute Lymphoblastic Leukemia (VHR ALL): A Single-Center Experience
Authors: Elena Vladimirovna Semenova, Olesia V Paina, Zhemal Zarifovna Rakhmanova, Polina Valerievna Kozhokar, Anastasia S Frolova, Kirill Alexandrovich Ekushov, Tatiana A Bykova, Anna Osipova, Inna V Markova, Sergey N. Bondarenko, Ildar Barhatov, Aleksandr Alyanski, Elena Babenko, Ivan S Moiseev, Ludmila S Zubarovskaya, Axel Zander, Boris V Afanasyev
Journal: Blood (2019)
COMP-12. SINGLE-CELL TRANSCRIPTOME PROFILING OF GBM TISSUE ACUTE SLICE CULTURES FOR PERSONALIZED DRUG SCREENING
Authors: Wenting Zhao, Eleonora Spinazzi, Athanassios Dovas, Pavan Upadhyayula, Tamara Marie, Michael Sisti, Jeff Bruce, Peter D Canoll, Peter Sims
Journal: Neuro-Oncology (2019)

Abstract Glioblastoma (GBM) is the most common and malignant type of primary brain tumor, and more effective treatment options are needed. Both inter- and intratumoral heterogeneity present major challenges to the application of targeted therapies in GBM. Therefore, precision medicine approaches to GBM would benefit significantly from the ability to predict drugs or drug combinations that target specific subpopulations of tumor cells. Model systems, such as adherent cell lines, neurospheres, patient-derived xenografts (PDXs), and patient-derived organoids, have been reported as platforms for drug screening and accessing drug responses. However, these models do not recapitulate the full heterogeneity of GBM tissue, lack key components of the tumor microenvironment or take weeks to months to establish, which limits the predictive power of drug response assays or delays clinical decision-making. To address these limitations, we are combining ex vivo slices of intact, patient-derived GBM tissue with single-cell RNA-seq (scRNA-seq) for small-scale drug screening and assessment of patient- and cell type-specific drug responses. We generated slices from both preclinical mouse glioma models and surgical specimens from GBM patients and showed that acute slices preserved both the tumor heterogeneity and tumor microenvironment observed in scRNA-seq of cells directly isolated from tumor tissue. To test drug responses, we treated tissue slices from GBM mouse models and five different patients with six drugs for 18hr. By performing scRNA-Seq and analyzing transcriptional profiles of treated and untreated control slices, we identified drug-induced transcriptional responses in specific subpopulations of tumor cells, patient-specific drug sensitivities, and drug effects conserved in both mouse and human tumors. The GBM tissue slices were generated immediately following surgical resection, and experiments were completed within 24 hours. With these features, our method is attractive for rapidly accessing cell type- and patient-specific drug responses and has potential for preclinical drug screening and guiding personalized treatment for GBM.
Transcriptomic Analysis Implicates Necroptosis in Disease Progression and Prognosis in Myelodysplastic Syndromes
Authors: Guillermo Montalban-Bravo, Caleb Class, Irene Ganan-Gomez, Rashmi Kanagal-Shamanna, Koji Sasaki, Guillaume Richard-Carpentier, Kiran Naqvi, Yue Wei, Hui Yang, Kelly Soltysiak, Kelly S. Chien, Carlos E. Bueso-Ramos, Kim-Anh Do, Hagop M. Kantarjian, Guillermo Garcia-Manero
Journal: Blood (2019)
Long-Time Follow-up of 888 Patients Diagnosed with CLL on a Single Center: Comorbidities, Time-to-Treatment and Comparison between Treated and Untreated Patients
Authors: Felix Keil, Lisa Obenaus, Victor Rathkolb, Michael Leiner, Robert Spörk, Elisabeth Koller, Ernst Forjan, Ralph Simanek, Michael Panny, Daniel Lechner, Alexandra Böhm, Anabel Schönmetzler, Theresia Kornberger, Thomas Noesslinger
Journal: Blood (2019)